In a phase 3 trial of 73 patients with advanced or refractory desmoid tumours, pegylated liposomal doxorubicin prolonged progression-free survival vs placebo (median not reached vs 4.3 months; HR 0.05). Grade ≥3 neutrophil decrease occurred in 10.6%.
RCTn = 73
Xu et al. Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors